



Product Information

Product ID C6132

CAS No. 1446144-04-2

Chemical Name

Synonym CPI203

Formula C₁₉H₁₈ClN₅OS

Formula Wt. 399.90

Melting Point 151.8°C


Purity ≥98%

Solubility DMSO 79 mg/mL warmed (197.54 mM)
Ethanol 5 mg/mL (12.5 mM)
Water Insoluble

Store Temp Ambient

Ship Temp Ambient

Description CPI-203 is an orally available derivative of triazolothienodiazepine JQ-1; it exhibits no sedative or anxiolytic efficacy and is currently in development as a potential anticancer compound. Like JQ-1, CPI-203 inhibits the BET bromodomain (BRD) family of proteins, including BRD4; inhibition of this protein downregulates Myc expression and IL-6 production in vitro. This compound also inhibits phosphorylation of the carboxyl-terminus domain of RNA polymerase II.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
C6132	1 mg	\$85.90
C6132	5 mg	\$280.50
C6132	25 mg	\$606.60

References King B, Trimarchi T, Reavie L, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. *Cell*. 2013 Jun 20;153(7):1552-66. PMID: 23791182.

Devaiah BN, Lewis BA, Cherman N, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. *Proc Natl Acad Sci U S A*. 2012 May 1;109(18):6927-32. PMID: 22509028.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.